Ellis Martin Report: Echo IQ Limited (ASX:EIQ) CEO Dustin Haines On FDA Progress And AI In Healthcare

(MENAFN- ABN Newswire) Sydney, April 22, 2026 AEST (ABN Newswire) - In this episode of The Ellis Martin Report, CEO Dustin Haines of Echo IQ Limited (ASX:EIQ ) (ECHQF:OTCMKTS ) discusses how artificial intelligence is transforming the early detection of cardiovascular disease.
Echo IQ is pioneering AI-driven diagnostic tools designed to help physicians detect heart conditions earlier and more accurately. With FDA clearance already secured for its aortic stenosis solution and a second product for heart failure currently under review, the company is positioning itself at the forefront of AI-powered healthcare innovation.
In this interview, Dustin Haines shares insights on:
- Echo IQ's rapid growth and global expansion
- FDA progress and upcoming catalysts
- Breakthrough heart failure detection with ~99.5% sensitivity
- The future of AI in healthcare, including wearables and predictive diagnostics
- Why cardiovascular disease remains a massive global opportunity
With over 200 million echocardiogram evaluations and collaborations with leading institutions like the Mayo Clinic, Echo IQ is aiming to redefine how heart disease is diagnosed and managed.
Learn more:
About Echo IQ Limited

Echo IQ Limited (ASX:EIQ) (OTCMKTS:ECHQF) use the AI-powered technology in EchoSolv to enhance the diagnosis of structural heart disease. Our mission is to help improve the lives of people by supporting earlier, more accurate detection of a number of life-threatening but often treatable conditions.

About The Ellis Martin Report
-p alt="Ellis Martin Report" src="https://abnnewswire.net/images/logos/37546en.jpg" />The Ellis Martin Report (TEMR) and Money Talk Radio feature interviews with industry leaders in mining, biotech, energy, and technology. The program is globally syndicated through multiple financial platforms and streaming services.

MENAFN21042026000111011020ID1111014079